2022
DOI: 10.46497/archrheumatol.2022.7931
|View full text |Cite
|
Sign up to set email alerts
|

Serum and Synovial Fluid Levels of Interleukin-17A in Primary Knee Osteoarthritis Patients: Correlations With Functional Status, Pain, and Disease Severity

Abstract: Objectives: This study aims to assess the serum and synovial fluid (SF) levels of interleukin (IL)-17A in primary knee osteoarthritis (KOA) patients and to study their correlations with functional status, pain, and disease severity. Patients and methods: This cross-sectional study was conducted between December 2017 and March 2018 and it included 70 patients (46 males, 24 females; mean age 57.3±10.0 years; range 34 to 76 years) with primary KOA and 30 age-, sex-, and body mass index-matched… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 29 publications
1
2
0
Order By: Relevance
“…The most important factor controlling OA is inflammatory cytokines, including IL-17 [ 27 ]. A prior work stated that IL-17A was highly expressed in the serum of patients with knee OA [ 53 ], which aligns with our experimental result.…”
Section: Discussionsupporting
confidence: 92%
“…The most important factor controlling OA is inflammatory cytokines, including IL-17 [ 27 ]. A prior work stated that IL-17A was highly expressed in the serum of patients with knee OA [ 53 ], which aligns with our experimental result.…”
Section: Discussionsupporting
confidence: 92%
“…Serum levels of IL-17A were significantly higher in knee OA patients than controls. ( 89 ) P49747 COMP Serum Up Longitudinal studies report higher serum COMP protein levels in patients who later demonstrate disease progression. Serum levels of COMP positive correlate with OA severity.…”
Section: Resultsmentioning
confidence: 99%
“…Elevated IL-17A levels were signi cantly linked to longer disease duration, increased pain scores, poorer quality of life, severe disability, and advanced structural damage. It is proposed that therapeutics targeting IL-17A should be further investigated (12) (13) (14). However, to achieve this, it is crucial to comprehend how and under what conditions IL-17A initiates joint tissue degeneration.…”
Section: Introductionmentioning
confidence: 99%